<DOC>
	<DOCNO>NCT02555124</DOCNO>
	<brief_summary>The purpose study evaluate safety JNJ-42847922 follow single oral administration .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability Pharmacokinetics JNJ-42847922 Healthy Japanese Male Participants</brief_title>
	<detailed_description>This single center , double-blind ( neither researcher participant know treatment participant receiving ) , placebo-controlled ( inactive substance ; pretend treatment [ drug ] compare clinical trial drug test drug real effect ) , randomize ( study medication assign participant chance ) , single-ascending dose study . The study consist screen phase , in-clinic treatment phase , follow-up phase . The study duration subject approximately 5 week screen ( Day -28 Day -3 ) , in-clinic period ( Day -2 Day 4 ) follow visit ( Day 8 ) . Participants receive single oral dose JNJ-42847922 placebo 3 cohort . Participants ' safety monitor throughout study .</detailed_description>
	<criteria>Participant must willing able adhere prohibition restriction specify inprotocol , Prohibitions Restrictions A man sexually active woman childbearing potential avasectomy must agree use adequate contraception method deem appropriate investigator ( eg , vasectomy , doublebarrier , partner use effective contraception ) , men must also agree donate sperm study 3 month afterreceiving last dose study drug Participant must body mass index ( BMI ) 18.0 29.9 kilogram per square meter ( kg/m^2 ) , body weight less 50 kg Participant must 12lead electrocardiogram ( ECG ) consistent normal cardiac conduction function , Including : Synus rhythm ; Heart rate 45 99 beat per minute ( bpm ) ; QT correct accord Fridericia 's formula ( QTcF ) interval less equal ( &lt; = ) 450 millisecond ( m ) ; QRS interval &lt; =120 m ; PR interval &lt; =220 m ; Morphology consistent healthy cardiac conduction function Nonsmoker ( smoke 3 month prior screen ) Participant history current clinically significant medical illness include ( notlimited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulationdisorders ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetesmellitus , hepatic renal insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness investigator considers exclude participant orthat could interfere interpretation study result Participant clinically significant abnormal value hematology , coagulation , biochemistry , urinalysis screening deem appropriate investigator Participant clinically significant abnormal physical examination , neurologic examination , vital sign deem appropriate investigator Use prescription nonprescription medication ( include vitamin herbalsupplements ) , except acetaminophen within 14 day study drug administration onDay 1 Participant know allergy , hypersensitivity , intolerance JNJ42847922 excipients</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-42847922</keyword>
</DOC>